Patricio A Godoy

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1380811/publications.pdf

Version: 2024-02-01

46 papers	4,223 citations	147801 31 h-index	214800 47 g-index
47 all docs	47 docs citations	47 times ranked	5202 citing authors

#	Article	IF	Citations
1	Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. Archives of Toxicology, 2013, 87, 1315-1530.	4.2	1,089
2	Adverse outcome pathways: opportunities, limitations and open questions. Archives of Toxicology, 2017, 91, 3477-3505.	4.2	282
3	Hepatocyte-Specific Smad7 Expression Attenuates TGF-Î²â€“Mediated Fibrogenesis and Protects Against Liver Damage. Gastroenterology, 2008, 135, 642-659.e46.	1.3	258
4	Extracellular matrix modulates sensitivity of hepatocytes to fibroblastoid dedifferentiation and transforming growth factor Î²-induced apoptosis. Hepatology, 2009, 49, 2031-2043.	7.3	217
5	Gene networks and transcription factor motifs defining the differentiation of stem cells into hepatocyte-like cells. Journal of Hepatology, 2015, 63, 934-942.	3.7	165
6	Toxicogenomics directory of chemically exposed human hepatocytes. Archives of Toxicology, 2014, 88, 2261-2287.	4.2	143
7	Protocols for staining of bile canalicular and sinusoidal networks of human, mouse and pig livers, three-dimensional reconstruction and quantification of tissue microarchitecture by image processing and analysis. Archives of Toxicology, 2014, 88, 1161-1183.	4.2	129
8	Interactome Screening Identifies the ER Luminal Chaperone Hsp47 as a Regulator of the Unfolded Protein Response Transducer IRE1Î±. Molecular Cell, 2018, 69, 238-252.e7.	9.7	127
9	Recombinant Laminins Drive the Differentiation and Self-Organization of hESC-Derived Hepatocytes. Stem Cell Reports, 2015, 5, 1250-1262.	4.8	123
10	The etiology of liver damage imparts cytokines transforming growth factor Î²1 or interleukin-13 as driving forces in fibrogenesis. Hepatology, 2009, 50, 230-243.	7.3	115
11	Model-guided identification of a therapeutic strategy to reduce hyperammonemia in liver diseases. Journal of Hepatology, 2016, 64, 860-871.	3.7	110
12	Profibrogenic transforming growth factor-Î²/activin receptor-like kinase 5 signaling via connective tissue growth factor expression in hepatocytes. Hepatology, 2007, 46, 1257-1270.	7.3	109
13	Gene network activity in cultivated primary hepatocytes is highly similar to diseased mammalian liver tissue. Archives of Toxicology, 2016, 90, 2513-2529.	4.2	100
14	Transcription factors ETF, E2F, and SP-1 are involved in cytokine-independent proliferation of murine hepatocytes. Hepatology, 2010, 52, 2127-2136.	7.3	95
15	Interferon-inducible guanylate binding protein (GBP2) is associated with better prognosis in breast cancer and indicates an efficient T cell response. Breast Cancer, 2014, 21, 491-499.	2.9	91
16	Bile Microinfarcts in Cholestasis Are Initiated by Rupture of the Apical Hepatocyte Membrane and Cause Shunting of Bile to Sinusoidal Blood. Hepatology, 2019, 69, 666-683.	7.3	89
17	Genotoxic stress triggers the activation of IRE1Î±-dependent RNA decay to modulate the DNA damage response. Nature Communications, 2020, 11, 2401.	12.8	62
18	The transcription factor CHOP, a central component of the transcriptional regulatory network induced upon CCl4 intoxication in mouse liver, is not a critical mediator of hepatotoxicity. Archives of Toxicology, 2014, 88, 1267-1280.	4.2	58

#	Article	IF	Citations
19	Distinct role of endocytosis for Smad and non-Smad TGF-Î² signaling regulation in hepatocytes. Journal of Hepatology, 2011, 55, 369-378.	3.7	55
20	Disruption of the Smad7 gene enhances CCl₄â€dependent liver damage and fibrogenesis in mice. Journal of Cellular and Molecular Medicine, 2008, 12, 2130-2144.	3.6	54
21	Definition of transcriptome-based indices for quantitative characterization of chemically disturbed stem cell development: introduction of the STOP-Toxukn and STOP-Toxukk tests. Archives of Toxicology, 2017, 91, 839-864.	4.2	53
22	Pharmacokinetics explain in vivo/in vitro discrepancies of carcinogen-induced gene expression alterations in rat liver and cultivated hepatocytes. Archives of Toxicology, 2013, 87, 337-345.	4.2	49
23	Human Hepatocytes: Isolation, Culture, and Quality Procedures. Methods in Molecular Biology, 2012, 806, 99-120.	0.9	46
24	TGF-Î²1 impairs mechanosensation of human osteoblasts via HDAC6-mediated shortening and distortion of primary cilia. Journal of Molecular Medicine, 2017, 95, 653-663.	3.9	46
25	Toxicogenomics directory of rat hepatotoxicants in vivo and in cultivated hepatocytes. Archives of Toxicology, 2018, 92, 3517-3533.	4.2	46
26	Dexamethasone-dependent versus -independent markers of epithelial to mesenchymal transition in primary hepatocytes. Biological Chemistry, 2010, 391, 73-83.	2.5	43
27	The virtual liver: state of the art and future perspectives. Archives of Toxicology, 2014, 88, 2071-2075.	4.2	41
28	Chronic CCl4 intoxication causes liver and bone damage similar to the human pathology of hepatic osteodystrophy: a mouse model to analyse the liverâ€“bone axis. Archives of Toxicology, 2014, 88, 997-1006.	4.2	41
29	Relevance of the incubation period in cytotoxicity testing with primary human hepatocytes. Archives of Toxicology, 2018, 92, 3505-3515.	4.2	41
30	Functional modulation of glycine receptors by the alkaloid gelsemine. British Journal of Pharmacology, 2016, 173, 2263-2277.	5.4	38
31	Interference with ERK-dimerization at the nucleocytosolic interface targets pathological ERK1/2 signaling without cardiotoxic side-effects. Nature Communications, 2020, 11, 1733.	12.8	38
32	Phenotype and growth behavior of residual Î²-catenin-positive hepatocytes in livers of Î²-catenin-deficient mice. Histochemistry and Cell Biology, 2010, 134, 469-481.	1.7	37
33	Inflammation-associated suppression of metabolic gene networks in acute and chronic liver disease. Archives of Toxicology, 2020, 94, 205-217.	4.2	32
34	Hepatotoxicity of piperazine designer drugs: up-regulation of key enzymes of cholesterol and lipid biosynthesis. Archives of Toxicology, 2016, 90, 3045-3060.	4.2	31
35	L-carnosine inhibits high-glucose-mediated matrix accumulation in human mesangial cells by interfering with TGF-Â production and signalling. Nephrology Dialysis Transplantation, 2011, 26, 3852-3858.	0.7	28
36	Assessment of stem cell differentiation based on genome-wide expression profiles. Philosophical Transactions of the Royal Society B: Biological Sciences, 2018, 373, 20170221.	4.0	26

#	Article	IF	Citations
37	Transcriptomic Crossâ€Species Analysis of Chronic Liver Disease Reveals Consistent Regulation Between Humans and Mice. Hepatology Communications, 2022, 6, 161-177.	4.3	24
38	Epigenomic and transcriptional profiling identifies impaired glyoxylate detoxification in NAFLD as a risk factor for hyperoxaluria. Cell Reports, 2021, 36, 109526.	6.4	22
39	Interfering with interferon-Î³ signalling in intestinal epithelial cells: selective inhibition of apoptosis-maintained secretion of anti-inflammatory interleukin-18 binding protein. Clinical and Experimental Immunology, 2010, 163, 65-76.	2.6	21
40	Reversible Manipulation of Apoptosis Sensitivity in Cultured Hepatocytes by Matrix-Mediated Manipulation of Signaling Activities. Methods in Molecular Biology, 2010, 640, 139-155.	0.9	17
41	Toxicogenomic-based approaches predicting liver toxicity in vitro. Archives of Toxicology, 2012, 86, 1163-1164.	4.2	14
42	Identification of RARRES1 as a core regulator in liver fibrosis. Journal of Molecular Medicine, 2012, 90, 1439-1447.	3.9	10
43	Alcohol hepatotoxicity: Kupffer cells surface to the top. Archives of Toxicology, 2012, 86, 1331-1332.	4.2	2
44	In Vitro Systems for Hepatotoxicity Testing. Methods in Pharmacology and Toxicology, 2014, , 27-44.	0.2	2
45	Highlight report: epoxide hydrolasesâ€”protection from reactive compounds and risk of cardiovascular disease. Archives of Toxicology, 2015, 89, 2463-2464.	4.2	2
46	Transcription factors controlling responses to toxic chemicals. Archives of Toxicology, 2013, 87, 3-4.	4.2	1